UK lessons to be learnt from US study showing healthcare system not ready for breakthrough dementia treatments

16 November 2017

The US healthcare system is not ready for potential breakthrough dementia treatments, according to a new Rand Corporation study released yesterday.

The report, “ Assessing the Preparedness of the U.S. Health Care System Infrastructure for an Alzheimer's Treatment,” is available at www.rand.org.

The study, commissioned by US biotech major Biogen (Nasdaq: BIIB), looked at the capacity of the current system to integrate new treatments. Alzheimer’s Research UK, the UK’s leading dementia research charity, is warning that similar roadblocks could impact the introduction of future dementia in the UK.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK